{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:17:06Z","timestamp":1773195426811,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"40","license":[{"start":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T00:00:00Z","timestamp":1326067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T00:00:00Z","timestamp":1326067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2012,10,4]]},"DOI":"10.1038\/onc.2011.604","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T17:26:49Z","timestamp":1326130009000},"page":"4384-4396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis"],"prefix":"10.1038","volume":"31","author":[{"given":"Y","family":"Sekine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Muromoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Oritani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,9]]},"reference":[{"key":"BFonc2011604_CR1","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.0900653106","volume":"106","author":"M Brehme","year":"2009","unstructured":"Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Kocher T et al. (2009). Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA 106: 7414\u20137419.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011604_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/leu.2008.337","volume":"23","author":"D Bruennert","year":"2009","unstructured":"Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R et al. (2009). Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 23: 983\u2013985.","journal-title":"Leukemia"},{"key":"BFonc2011604_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857\u2013868.","journal-title":"Cell"},{"key":"BFonc2011604_CR4","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1038\/onc.2009.260","volume":"28","author":"YC Chang","year":"2009","unstructured":"Chang YC, Tien SC, Tien HF, Zhang H, Bokoch GM, Chang ZF . (2009). p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells. Oncogene 28: 4105\u20134115.","journal-title":"Oncogene"},{"key":"BFonc2011604_CR5","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-06-4312","volume":"67","author":"S Chu","year":"2007","unstructured":"Chu S, Li L, Singh H, Bhatia R . (2007). BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res 67: 7045\u20137053.","journal-title":"Cancer Res"},{"key":"BFonc2011604_CR6","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"AS Corbin","year":"2003","unstructured":"Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW . (2003). Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101: 4611\u20134614.","journal-title":"Blood"},{"key":"BFonc2011604_CR7","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S et al. (2007). Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110: 4005\u20134011.","journal-title":"Blood"},{"key":"BFonc2011604_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","volume":"106","author":"LC Crossman","year":"2005","unstructured":"Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE . (2005). hOCT 1 and resistance to imatinib. Blood 106: 1133\u20131134; author reply 1134.","journal-title":"Blood"},{"key":"BFonc2011604_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","volume":"91","author":"SR Datta","year":"1997","unstructured":"Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231\u2013241.","journal-title":"Cell"},{"key":"BFonc2011604_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.278.5338.687","volume":"278","author":"L del Peso","year":"1997","unstructured":"del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687\u2013689.","journal-title":"Science"},{"key":"BFonc2011604_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. (2003). BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690\u2013698.","journal-title":"Blood"},{"key":"BFonc2011604_CR12","first-page":"625","volume":"9","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al. (2003a). Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9: 625\u2013632.","journal-title":"Clin Cancer Res"},{"key":"BFonc2011604_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . (2003b). Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4: 75\u201385.","journal-title":"Lancet Oncol"},{"key":"BFonc2011604_CR14","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/0008-5472.CAN-04-2152","volume":"65","author":"JF Geay","year":"2005","unstructured":"Geay JF, Buet D, Zhang Y, Foudi A, Jarrier P, Berthebaud M et al. (2005). p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 65: 2676\u20132683.","journal-title":"Cancer Res"},{"key":"BFonc2011604_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876\u2013880.","journal-title":"Science"},{"key":"BFonc2011604_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Rosee P . (2004). Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18: 1321\u20131331.","journal-title":"Leukemia"},{"key":"BFonc2011604_CR17","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","volume":"107","author":"A Hoelbl","year":"2006","unstructured":"Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y et al. (2006). Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 107: 4898\u20134906.","journal-title":"Blood"},{"key":"BFonc2011604_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28\u201337.","journal-title":"Blood"},{"key":"BFonc2011604_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1349-7006.2010.01842.x","volume":"102","author":"O Ikeda","year":"2011","unstructured":"Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A et al. (2011). Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. Cancer Sci 102: 756\u2013761.","journal-title":"Cancer Sci"},{"key":"BFonc2011604_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","volume":"7","author":"L Jin","year":"2008","unstructured":"Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H et al. (2008). CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7: 48\u201358.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2011604_CR21","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","volume":"95","author":"P le Coutre","year":"2000","unstructured":"le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G et al. (2000). Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 1758\u20131766.","journal-title":"Blood"},{"key":"BFonc2011604_CR22","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1056\/NEJMp038130","volume":"349","author":"B Lowenberg","year":"2003","unstructured":"Lowenberg B . (2003). Minimal residual disease in chronic myeloid leukemia. N Engl J Med 349: 1399\u20131401.","journal-title":"N Engl J Med"},{"key":"BFonc2011604_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1074-7613(00)80046-1","volume":"10","author":"Q Ma","year":"1999","unstructured":"Ma Q, Jones D, Springer TA . (1999). The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10: 463\u2013471.","journal-title":"Immunity"},{"key":"BFonc2011604_CR24","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. (2000). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070\u20131079.","journal-title":"Blood"},{"key":"BFonc2011604_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. (2010). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFonc2011604_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1385\/IR:36:1:61","volume":"36","author":"YK Mburu","year":"2006","unstructured":"Mburu YK, Wang J, Wood MA, Walker WH, Ferris RL . (2006). CCR7 mediates inflammation-associated tumor progression. Immunol Res 36: 61\u201372.","journal-title":"Immunol Res"},{"key":"BFonc2011604_CR27","doi-asserted-by":"publisher","first-page":"11182","DOI":"10.1074\/jbc.M211230200","volume":"278","author":"M Minoguchi","year":"2003","unstructured":"Minoguchi M, Minoguchi S, Aki D, Joo A, Yamamoto T, Yumioka T et al. (2003). STAP-2\/BKS, an adaptor\/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif. J Biol Chem 278: 11182\u201311189.","journal-title":"J Biol Chem"},{"key":"BFonc2011604_CR28","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1038\/sj.onc.1203775","volume":"19","author":"PJ Mitchell","year":"2000","unstructured":"Mitchell PJ, Sara EA, Crompton MR . (2000). A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene 19: 4273\u20134282.","journal-title":"Oncogene"},{"key":"BFonc2011604_CR29","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW . (2007). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242\u20132249.","journal-title":"Blood"},{"key":"BFonc2011604_CR30","doi-asserted-by":"publisher","first-page":"19929","DOI":"10.1074\/jbc.273.32.19929","volume":"273","author":"M Pap","year":"1998","unstructured":"Pap M, Cooper GM . (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase\/Akt cell survival pathway. J Biol Chem 273: 19929\u201319932.","journal-title":"J Biol Chem"},{"key":"BFonc2011604_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1126\/science.283.5403.845","volume":"283","author":"A Peled","year":"1999","unstructured":"Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T et al. (1999). Dependence of human stem cell engraftment and repopulation of NOD\/SCID mice on CXCR4. Science 283: 845\u2013848.","journal-title":"Science"},{"key":"BFonc2011604_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0092-8674(91)90148-R","volume":"66","author":"AM Pendergast","year":"1991","unstructured":"Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON . (1991). BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66: 161\u2013171.","journal-title":"Cell"},{"key":"BFonc2011604_CR33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nm1127","volume":"10","author":"A Ptasznik","year":"2004","unstructured":"Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . (2004). Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10: 1187\u20131189.","journal-title":"Nat Med"},{"key":"BFonc2011604_CR34","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J . (2009). Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619\u20131630.","journal-title":"Blood"},{"key":"BFonc2011604_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R . (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172\u2013183.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2011604_CR36","first-page":"4233","volume":"94","author":"R Salgia","year":"1999","unstructured":"Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS et al. (1999). The BCR\/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 94: 4233\u20134246.","journal-title":"Blood"},{"key":"BFonc2011604_CR37","first-page":"839","volume":"12","author":"M Sattler","year":"1996","unstructured":"Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E et al. (1996). The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR\/ABL and p210BCR\/ABL to the phosphatidylinositol-3\u2032 kinase pathway. Oncogene 12: 839\u2013846.","journal-title":"Oncogene"},{"key":"BFonc2011604_CR38","doi-asserted-by":"publisher","first-page":"7966","DOI":"10.4049\/jimmunol.0902096","volume":"183","author":"Y Sekine","year":"2009","unstructured":"Sekine Y, Ikeda O, Tsuji S, Yamamoto C, Muromoto R, Nanbo A et al. (2009a). Signal-transducing adaptor protein-2 regulates stromal cell-derived factor-1 alpha-induced chemotaxis in T cells. J Immunol 183: 7966\u20137974.","journal-title":"J Immunol"},{"key":"BFonc2011604_CR39","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbrc.2007.03.031","volume":"356","author":"Y Sekine","year":"2007","unstructured":"Sekine Y, Tsuji S, Ikeda O, Kakisaka M, Sugiyama K, Yoshimura A et al. (2007a). Leukemia inhibitory factor-induced phosphorylation of STAP-2 on tyrosine-250 is involved in its STAT3-enhancing activity. Biochem Biophys Res Commun 356: 517\u2013522.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2011604_CR40","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.4049\/jimmunol.179.4.2397","volume":"179","author":"Y Sekine","year":"2007","unstructured":"Sekine Y, Tsuji S, Ikeda O, Sugiyma K, Oritani K, Shimoda K et al. (2007b). Signal-transducing adaptor protein-2 regulates integrin-mediated T cell adhesion through protein degradation of focal adhesion kinase. J Immunol 179: 2397\u20132407.","journal-title":"J Immunol"},{"key":"BFonc2011604_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bbrc.2009.04.109","volume":"384","author":"Y Sekine","year":"2009","unstructured":"Sekine Y, Yamamoto C, Ikeda O, Muromoto R, Nanbo A, Oritani K et al. (2009b). The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl. Biochem Biophys Res Commun 384: 187\u2013192.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2011604_CR42","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.1074\/jbc.M411692200","volume":"280","author":"Y Sekine","year":"2005","unstructured":"Sekine Y, Yamamoto T, Yumioka T, Sugiyama K, Tsuji S, Oritani K et al. (2005). Physical and functional interactions between STAP-2\/BKS and STAT5. J Biol Chem 280: 8188\u20138196.","journal-title":"J Biol Chem"},{"key":"BFonc2011604_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4049\/jimmunol.176.1.380","volume":"176","author":"Y Sekine","year":"2006","unstructured":"Sekine Y, Yumioka T, Yamamoto T, Muromoto R, Imoto S, Sugiyma K et al. (2006). Modulation of TLR4 signaling by a novel adaptor protein signal-transducing adaptor protein-2 in macrophages. J Immunol 176: 380\u2013389.","journal-title":"J Immunol"},{"key":"BFonc2011604_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117\u2013125.","journal-title":"Cancer Cell"},{"key":"BFonc2011604_CR45","doi-asserted-by":"publisher","first-page":"31774","DOI":"10.1074\/jbc.M110.118653","volume":"285","author":"M Tokunaga","year":"2010","unstructured":"Tokunaga M, Ezoe S, Tanaka H, Satoh Y, Fukushima K, Matsui K et al. (2010). BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1\/WAF1. J Biol Chem 285: 31774\u201331782.","journal-title":"J Biol Chem"},{"key":"BFonc2011604_CR46","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/ncb1193","volume":"6","author":"T Toyofuku","year":"2004","unstructured":"Toyofuku T, Zhang H, Kumanogoh A, Takegahara N, Yabuki M, Harada K et al. (2004). Guidance of myocardial patterning in cardiac development by Sema6D reverse signalling. Nat Cell Biol 6: 1204\u20131211.","journal-title":"Nat Cell Biol"},{"key":"BFonc2011604_CR47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83: 258\u2013264.","journal-title":"Clin Pharmacol Ther"},{"key":"BFonc2011604_CR48","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD . (2000). Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines. Blood 95: 3498\u20133505.","journal-title":"Blood"},{"key":"BFonc2011604_CR49","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE et al. (2001). Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20: 6188\u20136195.","journal-title":"Oncogene"},{"key":"BFonc2011604_CR50","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0006-291X(03)01042-8","volume":"306","author":"T Yamamoto","year":"2003","unstructured":"Yamamoto T, Yumioka T, Sekine Y, Sato N, Minoguchi M, Yoshimura A et al. (2003). Regulation of FcepsilonRI-mediated signaling by an adaptor protein STAP-2\/BSK in rat basophilic leukemia RBL-2H3 cells. Biochem Biophys Res Commun 306: 767\u2013773.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2011604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011604","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:40:42Z","timestamp":1647888042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2011604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,9]]},"references-count":50,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2012,10,4]]}},"alternative-id":["BFonc2011604"],"URL":"https:\/\/doi.org\/10.1038\/onc.2011.604","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,9]]},"assertion":[{"value":"19 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}